News stories about Glaukos (NYSE:GKOS) have been trending somewhat positive recently, Accern reports. The research group scores the sentiment of media coverage by monitoring more than twenty million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Glaukos earned a news impact score of 0.13 on Accern’s scale. Accern also assigned news articles about the medical instruments supplier an impact score of 45.3589872902322 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.

Here are some of the news articles that may have impacted Accern Sentiment Analysis’s rankings:

GKOS has been the topic of several research analyst reports. Stifel Nicolaus reiterated a “buy” rating on shares of Glaukos in a research report on Thursday, September 14th. BidaskClub raised shares of Glaukos from a “sell” rating to a “hold” rating in a research note on Friday, September 1st. Cantor Fitzgerald reissued a “buy” rating and set a $60.00 target price on shares of Glaukos in a research note on Tuesday, November 7th. Piper Jaffray Companies reissued a “buy” rating and set a $38.00 target price on shares of Glaukos in a research note on Friday, September 15th. Finally, BMO Capital Markets reissued a “buy” rating and set a $54.00 target price on shares of Glaukos in a research note on Friday, September 1st. Two investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. The stock currently has an average rating of “Buy” and a consensus price target of $46.57.

Shares of Glaukos (NYSE:GKOS) opened at $26.47 on Monday. Glaukos has a 52 week low of $23.08 and a 52 week high of $52.49. The stock has a market cap of $914.94 and a price-to-earnings ratio of 220.58.

Glaukos (NYSE:GKOS) last released its quarterly earnings data on Tuesday, November 7th. The medical instruments supplier reported $0.04 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.02) by $0.06. Glaukos had a negative net margin of 0.64% and a positive return on equity of 3.50%. The business had revenue of $40.41 million during the quarter, compared to analyst estimates of $38.69 million. During the same quarter in the previous year, the business earned $0.03 EPS. Glaukos’s quarterly revenue was up 36.6% compared to the same quarter last year. equities research analysts predict that Glaukos will post -0.03 earnings per share for the current year.

In other Glaukos news, CFO Joseph E. Gilliam acquired 2,100 shares of Glaukos stock in a transaction that occurred on Wednesday, November 22nd. The stock was acquired at an average price of $23.84 per share, with a total value of $50,064.00. Following the purchase, the chief financial officer now owns 102,100 shares in the company, valued at $2,434,064. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 16.40% of the stock is currently owned by insiders.

ILLEGAL ACTIVITY NOTICE: This report was originally published by Daily Political and is the sole property of of Daily Political. If you are reading this report on another domain, it was illegally stolen and republished in violation of international copyright & trademark laws. The legal version of this report can be viewed at

Glaukos Company Profile

Glaukos Corporation is an ophthalmic medical technology company. The Company focuses on the development and commercialization of products and procedures for the treatment of glaucoma. It offers iStent, a micro-invasive glaucoma surgery (MIGS) device. The iStent is a micro-bypass stent inserted through the small corneal incision made during cataract surgery and placed into Schlemm’s canal, a circular channel in the eye that collects aqueous humor and delivers it back into the bloodstream.

Insider Buying and Selling by Quarter for Glaukos (NYSE:GKOS)

Receive News & Ratings for Glaukos Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Glaukos and related companies with's FREE daily email newsletter.